Navigation Links
Immucor Announces Fiscal First Quarter Results
Date:10/1/2009

NORCROSS, Ga., Oct. 1 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today reported financial results for its fiscal 2010 first quarter ended August 31, 2009.

Financial Highlights

  • Revenue for the fiscal first quarter of 2010 was $83.1 million, up 14% from $73.2 million in the prior year quarter.
  • Gross margin was 71.9% in the quarter, compared with 73.0% in the prior year quarter. Current quarter gross margin included expenses of approximately $2.3 million related to the Quality Process Improvement Project.
  • Net income in the quarter was $21.3 million, compared with $20.0 million for the same quarter last year.
  • Diluted earnings per share totaled $0.30 in the quarter, compared with $0.28 for the same period last year. The current year quarter included the impact from the Quality Process Improvement Project of approximately $0.02 per diluted share, net of tax.
  • Cash flow from operations for the quarter ended August 31, 2009 was $24.5 million, compared with $21.6 million in the prior year.
  • The current year included a full quarter of results for BioArray Solutions, which was acquired on August 4, 2008.

"Despite the economy, we continue to generate revenue, earnings and cash flow growth due to the needs-based aspect of our business and our focus on automation that improves blood bank operations," stated Dr. Gioacchino De Chirico, Immucor's President and Chief Executive Officer. 

    Selected Product Revenue and Gross Margin
                                       ($ amounts in thousands)    Revenue
                       Fiscal Q1 2010      Fiscal Q1 2009          Growth
                       --------------      --------------          -----
'/>"/>
SOURCE  Immucor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... , Switzerland , February 9 ... global biopharmaceutical group of companies with,a focus ... target unmet medical,needs, today announced the signature ... the development, manufacture and commercialisation of Debio ... with a,potent anti-hepatitis C virus (HCV) effect. ...
(Date:2/8/2010)... PreXion, Inc., ( www.prexion.com ) the ... for dentistry, today announced that it has appointed ... PreXion President/COO Robert Meier commented, "We are ... and I look forward to working with him in ... and success in the dental and high tech medical ...
(Date:2/8/2010)... Feb. 8 Rapid developments ... steady increase in the use and cost of ... arthritis and psoriasis. This has led to some ... costs and medication coverage being spread over both ... new solution with Medication Cost Integration (MCI), which ...
Breaking Medicine Technology:Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3PreXion, Inc. Announces Appointment of Director of Marketing 2RegenceRx Leads the Industry With Introduction of Medication Cost Integration 2RegenceRx Leads the Industry With Introduction of Medication Cost Integration 3Doctor Building Nutritarian Army to Fight Disease 65240 1Doctor Building Nutritarian Army to Fight Disease 65240 2Doctor Building Nutritarian Army to Fight Disease 65240 3Hakuna Staff Scheduling Software is Proud To Announce the Launch of Its Online Employee Scheduling Program 65238 1Hakuna Staff Scheduling Software is Proud To Announce the Launch of Its Online Employee Scheduling Program 65238 2Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone 15419 1Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone 15419 2Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone 15419 3
... - Results from phase III,clinical trials and further ... of the European Academy of,Dermatology and Venereology (EADV). ... alitretinoin as a potential once,daily oral treatment for ... no approved treatment exists for severe Chronic Hand,Eczema ...
... MENLO PARK, Calif.--(BUSINESS WIRE)--May,21, 2007 - ChemGenex ... of new clinical data relevant to the ... and the T315I mutation in Philadelphia-positive leukemias",by ... University of,Bologna, Italy (Haematologica Volume 92, pages ...
Other Medicine Technology:Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 2Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 3Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 5Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3
(Date:2/9/2010)... the Heart with "The Heart-Smart Diabetes ... 9 Show your love this ... the heart with the new cookbook "The Heart-Smart ... Canola Oil" by the American Diabetes Association (ADA) and ... love or give the cookbook as a gift, you ...
(Date:2/9/2010)... LA JOLLA, CA-- Dana-Farber Cancer Institute and the ... agreement with Genentech, a wholly owned member of ... companies exclusive rights to manufacture, develop and market ... group 1 influenza viruses. These viruses include the ... Genentech and Roche also have a non-exclusive right ...
(Date:2/9/2010)... Cancer Center of University Hospitals (UH) Case Medical Center, ... new standard of care for patients with locally advanced ... of Clinical Cancer Research, the phase one ... well tolerated in combination with standard-of-care cisplatin chemotherapy and ... provided both significant reduction in cancer disease and cancer ...
(Date:2/9/2010)... The research group of Dr. Franois Robert, a researcher ... in collaboration with the team of Dr. Daniel Durocher ... a technical breakthrough: they mapped all the fragile sites ... cerevisiae . The method used by the researchers can ... online today in the scientific journal Nature Structural ...
(Date:2/9/2010)... MINNEAPOLIS/ST.PAUL (February 8, 2010)- Consuming two or more soft ... cancer by nearly two-fold compared with individuals who did ... Cancer Epidemiology, Biomarkers & Prevention , a journal ... Although relatively rare, pancreatic cancer remains one of the ... diagnosed survive five years later. , Mark Pereira, Ph.D., ...
Breaking Medicine News(10 mins):Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 2Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 3Health News:Soft drinks may increase risk of pancreatic cancer 2
... CEO, American Association of,Homes and Services for the ... Exceptions Process, WASHINGTON, July 2 Following ... American Association of Homes and,Services for the Aging, ... Process:, "Medicare beneficiaries are once again having ...
... American Medical,Association Foundation announced the election today of ... of Traverse City, Michigan, is finishing her fifth ... is the first Alliance,representative to be President of ... President, President-Elect, Treasurer, Finance,Committee Chair, Secretary, Bylaws Committee ...
... water ... needed to fight fire, VANCOUVER, British Columbia, July 2 ... house fire, Shelter,Island Fire Department First Assistant Fire Chief William Rowland made ... FIT-5,a new handheld fire interruption device that quickly knocked down a,basement fire ...
... NORTH ANDOVER, Mass., July 2 Does your ... shows that upwards of 10.7,million pets in the ... unwanted behaviors. While the trend toward the use ... and other,complex stress-related emotions is on the rise, ...
... as most common reason for hospitalizations, analysis finds , , ... than 1.2 million Americans -- roughly equivalent to the ... federal government analysis of hospital admissions and costs found. ... most common reason for admission to hospital, and treating ...
... 2 David Belkin died,last February during a pick-up basketball ... alive to tell about it., On Sunday, July 6 ... present Matlaga with the Sudden Cardiac Arrest (SCA) Foundation,s,People Saving ... at,13 Hillcrest Rd. (behind Wayne Memorial Hospital) in Honesdale., ...
Other Medicine News:Health News:AAHSA Statement: Therapy Caps Ration Care 2Health News:AMA Foundation Names Jean Howard President 2Health News:Home in Prominent Shelter Island, New York, Ablaze; Saved by the FIT-5 Fire Fighting Device 2Health News:Natural Remedies to Treat Animals' Complex Emotions 2Health News:Back From the Dead: Cardiac Arrest Victim Salutes His Rescuer 2
... Healing Shoe offers the most advanced design ... allowing patients to maintain their mobility. Thanks ... even larger portion of the forefoot is ... heads and toes to heal faster. OrthoWedge ...
The choice for inclement weather. This boot provides both closed toe and heel with a moisture resistant vinyl upper....
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
Medicine Products: